SCHEMBL22209663

SCHEMBL22209663

CC(C)(C)C1C2CC1CN(c1ccccc1)C2

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BPTF Q12830 1/20 0.53
GPR119 Q8TDV5 1/20 0.38
CHRNA7 P36544 3/20 0.37
CHRNB2 P17787 2/20 0.37
CHRNA4 P43681 2/20 0.37
CYP3A4 P08684 1/20 0.37
ALOX15 P16050 1/20 0.37
NFKB1 P19838 1/20 0.37
MAPK1 P28482 1/20 0.37
CHRNA3 P32297 1/20 0.37
HSD17B10 Q99714 1/20 0.37
MEN1 O00255 1/20 0.36
POLB P06746 1/20 0.36
APOBEC3A P31941 1/20 0.36
PMP22 Q01453 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HIF1A Q16665 1/20 0.36
APOBEC3G Q9HC16 1/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22209763 0.82 BPTF (0.46) BPTFGPR119CHRNA7CHRNB2CHRNA4
SCHEMBL23951656 0.78 BPTF (0.48) BPTFGPR119CHRNA7CHRNB2CHRNA4
SCHEMBL15515714 0.73 BPTF (0.63) BPTFGPR119CHRNA7CHRNB2CHRNA4
SCHEMBL20858814 0.72 BPTF (0.57) BPTFCYP3A4HSD17B10NOTUMSIGMAR1
SCHEMBL18436512 0.71 BPTF (0.50) BPTFCHRNA7CHRNB2CHRNA4CYP3A4
SCHEMBL27318032 0.71 BPTF (0.61) BPTFMEN1KMT2ASMN1; SMN2NOTUM
SCHEMBL18701824 0.70 BPTF (0.46) BPTFGPR119MAPK1MEN1KMT2A
SCHEMBL19139371 0.70 BPTF (0.54) BPTFCHRNA7CHRNB2CHRNA4CYP3A4
SCHEMBL26496330 0.70 BPTF (0.54) BPTFCHRNA7CHRNB2CHRNA4CYP3A4
SCHEMBL10263800 0.69 BPTF (1.00) BPTFCHRNA7CHRNB2CHRNA4CHRNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10711004-B2 Oxadiazole transient receptor potential channel inhibitors GENENTECH, INC. (US) 2020-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10711004-B2 Oxadiazole transient receptor potential channel inhibitors TRPA1, TRPV1, TRPV3 BPTF 4510/4885GPR119 488/4885CHRNA7 670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.